Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2007 1
2008 1
2010 1
2011 2
2012 2
2013 1
2014 4
2015 2
2018 1
2019 1
2020 4
2021 4
2022 9
2023 5
2024 2

Text availability

Article attribute

Article type

Publication date

Search Results

36 results

Results by year

Filters applied: . Clear all
Page 1
Lymphadenopathy Associated With the COVID-19 Vaccine.
Hiller N, Goldberg SN, Cohen-Cymberknoh M, Vainstein V, Simanovsky N. Hiller N, et al. Among authors: vainstein v. Cureus. 2021 Feb 23;13(2):e13524. doi: 10.7759/cureus.13524. Cureus. 2021. PMID: 33786231 Free PMC article.
Monitoring Minimal Residual Disease in RUNX1-Mutated Acute Myeloid Leukemia.
Nachmias B, Krichevsky S, Filon D, Even-Or E, Gatt ME, Saban R, Avni B, Grisariu S, Aumann S, Vainstein V. Nachmias B, et al. Among authors: vainstein v. Acta Haematol. 2022;145(6):642-649. doi: 10.1159/000526353. Epub 2022 Aug 5. Acta Haematol. 2022. PMID: 35933982 Free PMC article.
Venetoclax is safe and efficacious in relapsed/refractory AML.
Ganzel C, Ram R, Gural A, Wolach O, Gino-Moor S, Vainstein V, Nachmias B, Apel A, Koren-Michowitz M, Pasvolsky O, Yerushalmi R, Danylesko I, Cohen Y, Peretz G, Moshe Y, Zektser M, Yeganeh S, Rowe JM, Ofran Y. Ganzel C, et al. Among authors: vainstein v. Leuk Lymphoma. 2020 Sep;61(9):2221-2225. doi: 10.1080/10428194.2020.1761964. Epub 2020 May 18. Leuk Lymphoma. 2020. PMID: 32420775
Rituximab, methotrexate, procarbazine and lomustine (R-MPL) for the treatment of primary Central nervous system lymphoma.
Lebel E, Goldschmidt N, Siegal T, Lossos A, Rosenberg S, Makranz C, Linetski E, Gatt ME, Gural A, Saban R, Lavie D, Vainstein V, Zimran E, Avni B, Grisaro S, Shaulov A, Nachmias B. Lebel E, et al. Among authors: vainstein v. Leuk Lymphoma. 2022 Sep;63(9):2102-2108. doi: 10.1080/10428194.2022.2064996. Epub 2022 May 2. Leuk Lymphoma. 2022. PMID: 35491706
Polatuzumab-based regimen or CAR T cell for patients with refractory/relapsed DLBCL-a matched cohort analysis.
Avivi I, Perry C, Segman Y, Amit O, Bar-On Y, Katz OB, Gold R, Ribakovsky E, Avigdor A, Vainstein V, Goldschmidt N, Ringelstein-Harlev S, Horowitz NA, Gutwein O, Gurion R, Itchaki G, Abadi U, Nemets A, Sofer O, Vezker M, Tadmor T, Dally N, Filanovsky K, Leiba M, Sarid N, Benyamini N, Luttwak E, Herishanu Y, Ram R. Avivi I, et al. Among authors: vainstein v. Ann Hematol. 2022 Apr;101(4):755-762. doi: 10.1007/s00277-021-04749-9. Epub 2022 Jan 27. Ann Hematol. 2022. PMID: 35083525
Gilteritinib monotherapy for relapsed/refractory FLT3 mutated acute myeloid leukemia: a real-world, multi-center, matched analysis.
Shimony S, Canaani J, Kugler E, Nachmias B, Ram R, Henig I, Frisch A, Ganzel C, Vainstein V, Moshe Y, Aumann S, Yeshurun M, Ofran Y, Raanani P, Wolach O. Shimony S, et al. Among authors: vainstein v. Ann Hematol. 2022 Sep;101(9):2001-2010. doi: 10.1007/s00277-022-04895-8. Epub 2022 Jun 24. Ann Hematol. 2022. PMID: 35739428
36 results